Canadians pay very high prices for generic drugs compared to international norms. The reason is not inefficient or noncompetitive generic drug companies, but provincial government pricing and insurance policies that are distorting the market. This paper by Professor Aidan Hollis, an expert in...

This paper offers an economic rationale for compulsory licensing of needed medicines in developing countries. The patent system is based on a trade-off between the “deadweight losses” caused by market power and the incentive to innovate created by increased profits from monopoly pricing...

Prompt and affordable access to essential medicines is a component of almost all domestic and global public health models. As is now well known, the availability and costs of both brand and generic drugs is a function of traditional patent law incentives. Less known, however, is that generic...